Elucidation of molecular mechanism of cellular toxicity of acrolein and its clinical application

2014 Fiscal Year Final Research Report

• Project/Area Number: 23390038
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Biological pharmacy
• Research Institution: Amine Pharma Research Institute Co., Ltd.
• Principal Investigator: IGARASHI Kazuei 株式会社アミンファーマ研究所, その他部局等, 代表取締役社長 (60089597)
• Co-Investigator(Kenkyū-buntansha): NISHIMURA Kazuhiro 千葉大学, 大学院薬学研究院, 准教授 (60302569) ; KASHIWAGI Keiko 千葉科学大学, 薬学部, 教授 (80169424)
• Project Period (FY): 2011-04-01 – 2015-03-31
• Keywords: 生体分子 / 生理活性 / 脳・神経 / バイオテクノロジー / ポリアミン / スペルミン / アクロレイン / グルタチオン

Outline of Final Research Achievements

We found the following in this research projects: 1) Acrolein caused inactivation of GAPDH, glyceraldehyde-3-phosphate dehydrogenase, as one mechanism of acrolein toxicity; 2) Acrolein was mainly detoxified by GSH (glutathione) in cells; 3) Theoretical background to measure PC-Acro, IL-6 and CRP in plasma for finding silent brain infarction was clarified; 4) Acrolein-conjugated LDL (low-density lipoprotein) induced macrophage foam cell formation, which is one of the reason of atherosclerosis lesions; and 5) Urinary 3-hydroxypropyl mercapturic acid (3-HPMA), an acrolein-glutathione metabolite, decreased in stroke patients.

Free Research Field

病態生化学